Dr. Gerno Schmiedeknecht, Head of the Department GMP Cell and Gene Therapy, Fraunhofer IZI, commented: “With the introduction of fully electronic batch documentation, manufacturing and batch release for our customers and partners will be even safer, faster, more cost-effective and generally more efficient. In addition, this measure leads to higher flexibility in a potential pandemic situation, as the process of reviewing the batch documentation and the batch release, in particular, can largely be carried out in remote mode without direct onsite presence.”
David McErlane, SVP, Head of Bioscience, Lonza, added: “We are excited to support Fraunhofer IZI with their MODA-ES® Implementation. Electronic batch records have been unattainable to most of the industry due to cost constraints and flexibility concerns. With a deep understanding of the challenges faced by cell and gene manufacturers, we designed MODA-ES® with the end user in mind to provide a cost-effective and usable solution that meets our customers’ requirements.”
The MODA® Platform bridges the gap between manufacturing and quality control, providing a mechanism to produce a single electronic batch record. Lonza’s manufacturing and lab execution software enables data capture and provides workflow and analytical tools to expedite product release. With a focus on a user-centric, scalable solution that may be implemented in an accelerated timeline, the MODA® Platform supports customers in their efforts to realize their digitalization goals.